Akeso's Ivonescimab Plus Chemotherapy Cuts Death Risk 25% in Phase III Biliary Tract Cancer Trial

• Akeso presented Phase III HARMONi-GI1 results for ivonescimab with chemotherapy in first-line advanced biliary tract cancer at ESMO 2026.
• The regimen improved overall survival, delayed disease progression and increased tumor responses compared with standard-of-care durvalumab with chemotherapy.
• Safety was manageable, with no new safety signals identified.
• Ivonescimab with chemotherapy has been proposed for priority review by China’s National Medical Products Administration for this indication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610251131PR_NEWS_USPR_____CN80427) on October 25, 2026, and is solely responsible for the information contained therein.